Genitourinary Cancer News

The FDA today issued new guidance to help drug developers select endpoints for marketing applications with the goal of advancing the efficient development of cancer drugs and biologics.

Pretreatment with sunitinib followed by deferred cytoreductive nephrectomy did not improve 28-week progression-free rates compared with immediate nephrectomy followed by sunitinib among patients with primary metastatic renal cell carcinoma, according to results of a phase 3 randomized trial published in JAMA Oncology.

The increasing prevalence of excess body weight, which was responsible for approximately 3.9% of all cancers worldwide in 2012, is driven by multiple economic and environmental factors and should be addressed through policy actions and other interventions, according to a report published in CA: A Cancer Journal for Clinicians.

SAN DIEGO — Rivaroxaban prophylaxis significantly reduced thromboembolic events among patients receiving systemic cancer therapy, according to findings of a double-blind, randomized, placebo-controlled study presented at the late-breaking abstract session of ASH Annual Meeting and Exposition.

SAN DIEGO — Patients with cancer-associated venous thromboembolism treated with oral apixaban appeared significantly less likely to experience VTE recurrence than those who received parenteral dalteparin, according to study results presented at ASH Annual Meeting and Exposition.

Stereotactic radiosurgery appeared comparable to surgical resection for controlling local brain metastases, according to an exploratory analysis of a randomized phase 3 trial.

CHICAGO — At the American Heart Association Scientific Sessions, HHS released the second edition of the Physical Activity Guidelines for Americans, which provides new recommendations for children and adolescents aged 3 years through 17 years.

Tivozanib extended PFS compared with sorafenib among patients with highly refractory advanced or metastatic renal cell carcinoma, according to randomized phase 3 study results released by the agent’s manufacturer.

ORLANDO, Fla. — A study presented at the AAP National Conference & Exhibition revealed that among young adult and adolescent cancer survivors, provider recommendation was the strongest predictor of intent to receive HPV vaccine, which, in turn, was strongly predictive of subsequent initiation of the vaccine series.

The FDA granted breakthrough therapy designation to UGN-101 for the treatment of patients with low-grade upper tract urothelial cancer, according to the agent’s manufacturer.